Latest Annual Filing
For Fiscal Year Ending June 30, 2023
Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new solid tumor cancer therapies.
VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase II clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase II/III trial as a therapy for the treatment of GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors.
REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second generation photosensitizer drug that has undergone late stage clinical development, and which we believe possesses multiple advantages over earlier generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy to use fiber optic wand that the physician employs to directly illuminate the tumor with light.
Kintara Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 150
San Diego, CA 92121